{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:38:08Z","timestamp":1776706688564,"version":"3.51.2"},"reference-count":14,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.mayocp.2020.03.001","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T08:01:18Z","timestamp":1596268878000},"page":"1604-1612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia\u2013Related Bleeding and High-Output Cardiac Failure"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6030-4418","authenticated-orcid":false,"given":"Hasan Ahmad Hasan","family":"Albitar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahya","family":"Almodallal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5783-305X","authenticated-orcid":false,"given":"Alice","family":"Gallo De Moraes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garret W.","family":"Choby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv K.","family":"Pruthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janalee K.","family":"Stokken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick S.","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector R.","family":"Cajigas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary M.","family":"DuBrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Krowka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6441-9319","authenticated-orcid":false,"given":"Vivek N.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9394","key":"10.1016\/j.mayocp.2020.03.001_bib1","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(03)14696-X","article-title":"Hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease)","volume":"362","author":"Fuchizaki","year":"2003","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.mayocp.2020.03.001_bib2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/jmg.40.7.494","article-title":"Visceral manifestations in hereditary haemorrhagic telangiectasia type 2","volume":"40","author":"Abdalla","year":"2003","journal-title":"J\u00a0Med Genet"},{"issue":"9","key":"10.1016\/j.mayocp.2020.03.001_bib3","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1513\/AnnalsATS.201603-200OC","article-title":"High rates of bleeding complications among hospitalized patients with hereditary hemorrhagic telangiectasia in the United States","volume":"13","author":"Brinjikji","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.mayocp.2020.03.001_bib4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jhep.2007.12.022","article-title":"Liver involvement in a large cohort of patients with hereditary hemorrhagic telangiectasia: echo-color-Doppler vs multislice computed tomography study","volume":"48","author":"Buonamico","year":"2008","journal-title":"J\u00a0Hepatol"},{"issue":"13","key":"10.1016\/j.mayocp.2020.03.001_bib5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJM200009283431305","article-title":"Liver disease in patients with hereditary hemorrhagic telangiectasia","volume":"343","author":"Garcia-Tsao","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2020.03.001_bib6","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2012.250","article-title":"Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output","volume":"307","author":"Dupuis-Girod","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mayocp.2020.03.001_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/joim.12832","article-title":"Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"285","author":"Al-Samkari","year":"2019","journal-title":"J\u00a0Intern Med"},{"issue":"2","key":"10.1016\/j.mayocp.2020.03.001_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding","volume":"93","author":"Iyer","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.mayocp.2020.03.001_bib9","first-page":"818","article-title":"Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression","volume":"90","author":"Sadick","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.mayocp.2020.03.001_bib10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00280-016-3079-6","article-title":"Population pharmacokinetics of bevacizumab in cancer patients with external validation","volume":"78","author":"Han","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.mayocp.2020.03.001_bib11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-019-1239-6","article-title":"Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers","volume":"14","author":"Al-Samkari","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.mayocp.2020.03.001_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacc.2016.05.043","article-title":"High-output heart failure: a 15-year experience","volume":"68","author":"Reddy","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.mayocp.2020.03.001_bib13","doi-asserted-by":"crossref","first-page":"e0188943","DOI":"10.1371\/journal.pone.0188943","article-title":"Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): a retrospective study of 46 patients","volume":"12","author":"Guilhem","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.mayocp.2020.03.001_bib14","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1111\/j.1755-3768.2009.01773.x","article-title":"Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis","volume":"89","author":"Forooghian","year":"2011","journal-title":"Acta Ophthalmol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619620302172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619620302172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:33:13Z","timestamp":1758418393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619620302172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0025619620302172"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2020.03.001","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia\u2013Related Bleeding and High-Output Cardiac Failure","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2020.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}